ClinicalTrials.gg
CompletedNCT06326723Updated Mar 22, 2024

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

A Phase 1 interventional study of Daridorexant in Healthy Volunteer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in 32 healthy adult Chinese subjects.

Read the detailed description

This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in healthy adult Chinese subjects. This study will consist of a 20-day screening period, a 1-day baseline, a 11-day in patient period, and a 27-day follow-up period. The subjects will arrive at the study site on Day -1, and the subjects will be discharged from the study site on Day11.

32 healthy subjects (18-55 years) will be randomized. Two dose levels are planned (25 mg and 50 mg). 16 healthy subjects will be randomized with a ratio of 3:1 to receive 25mg daridorexant or matched placebo and another 16 healthy subjects will be randomized with a ratio of 3:1 to receive 50mg daridorexant or matched placebo. On Day 1, each subject will receive a single dose of daridorexant or placebo in the morning under fast conditions and PK samples will be collected up to 72 h post dose. Subject will receive repeated doses of daridorexant or placebo from day 4 to day 8 (QD) in the morning under fasting conditions and PK samples will be collected up to 72 h post last dose. The final follow-up visit will be conducted on Day 38, 30 days after the last dose.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study. Signed in the local language prior to any study-mandated procedure.
  2. Healthy Chinese male or female subjects aged between 18 and 55 years (inclusive) at screening.
  3. (BMI) ≥ 19 and ≤ 26 kg/m2, weight at least 45 kg for female, weight at least 50 kg for male at screening.
  4. General good health at screening, with no abnormalities or abnormal clinically insignificant results based on medical history and physical examination, vital signs, laboratory tests, and 12-lead performed at the time of screening. 50 bpm≤Resting heart rate (HR)≤100 bpm, 90mmHg \<systolic blood pressure\<140 mmHg or 50 mmHg\<diastolic blood pressure\<90 mmHg, ECG evidence of a interval of no more than 450 ms for male, ECG evidence of a QTcF interval of no more than 470 ms for female, (ECG monitors will be conducted for three times in five minutes, and mean values of three monitor results will be used)
  5. Negative results from alcohol breath test and urine drug screen at Day -1.
  6. Subjects (including male subjects) are willing to voluntarily use effective from screening visit until 30 days after the end of the last dose and had no plans to become pregnant, planned parenthood or sperm/egg donation plans; Or subjects after surgical sterilization, or female subjects (female subjects with natural menopause ≥12 months can be considered postmenopausal; If age \<50 years by follicle stimulating hormone level confirmed)

Exclusion criteria

Exclusion Criteria:

  1. Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  2. Intubation or repeat venipuncture is not appropriate.
  3. Treatment with any prescription medications or over-the-counter medications (including herbal medicines) within 14 days prior to (first) study drug administration.
  4. Have received any vaccine (including COVID-19 vaccine) prior to screening; have plan to receive vaccine (COVID-19 vaccine) during the study period or within 30 days after the last dose.
  5. Not able or willing to stop treatment with moderate or strong cytochrome P450 (CYP)3A4 inhibitors, or treatment with moderate or strong inducers, within 14 days prior to (first) study drug administration.
  6. Not able or willing to stop consumption of grapefruit, Seville (bitter) oranges or juices from those fruits within 14 days prior to (first) study drug administration.
  7. Treatment with another drug within 3 months prior to screening or having participated in more than four investigational drug studies within 1 year prior to screening.
  8. Use any nicotine or tobacco containing products (>5 cigarettes/day) within 3 years prior to day 1 and inability to refrain from smoking during the study.
  9. Alcohol abuse(≥ 14 standard drinks units per week; 1 unit: 285 mL beer or 25 mL spirits or 100 mL wine) within 3 years prior to day 1 and inability to refrain from taking alcohol during the study.
  10. Drinking excessive tea (>15 g tea leaves/day; 1 cup of tea contains about 3\~5 g of tea leaves) or caffeine (>500 mg/ day, 1 cup of coffee contains about 85 mg of caffeine) and inability to refrain from drinking tea or caffeinated beverage during the study.
  11. History or clinical evidence of any disease, and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study drugs (appendectomy and herniotomy allowed; cholecystectomy not allowed).
  12. History of drug abuse.
  13. Loss of 400 mL or more of blood, or an equivalent amount of plasma, within 3 months prior to screening.
  14. Positive result to any of the following tests: , , , and syphilis.
  15. Known to any of the drug formulations.
  16. Modified Swiss Narcolepsy Scale total score \< 0 at screening. History of narcolepsy or cataplexy.
  17. Any surgery planned during the study period.
  18. Legal incapacity or limited legal capacity at screening
  19. History of tuberculosis (TB).
  20. Pregnant or lactating women, or positive pregnancy test results.
  21. Any suicidal ideation with intent, with or without a plan (at screening):

    Planned or unplanned any suicidal thoughts; That is, answer yes to question 4 or 5 of the Suicidal ideation section of the lifetime version C-SSRS©. Lifetime past C-SSRS© Suicidal Behavior section indicates a history of suicide attempts.

  22. Any circumstances or conditions which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    25mg group

    Dose:25mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)

    Drug: Daridorexant

  • Experimental
    50mg group

    Dose:50mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)

    Drug: Daridorexant

Interventions

  • 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8. Placebo control group: administered in the same manner as the test drug. 50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8. Placebo control group: administered in the same manner as the test drug. Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Endpoints1

    Maximum plasma concentration (Cmax)

    Time frame: Day1-Day11

  2. Pharmacokinetic Endpoints2

    Area under the concentration-time curve from zero to 24 hours (AUC0-24)

    Time frame: Day1-Day11

  3. Pharmacokinetic Endpoints3

    Aarea under the concentration-time curve from zero to 48 hours (AUC0-48)

    Time frame: Day1-Day11

  4. Pharmacokinetic Endpoints4

    Area under the concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t)

    Time frame: Day1-Day11

  5. Pharmacokinetic Endpoints5

    area under the concentration-time curve from zero to infinity (AUC0-∞)

    Time frame: Day1-Day11

  6. Pharmacokinetic Endpoints6

    Time to reach maximum concentration (Tmax)

    Time frame: Day1-Day11

  7. Pharmacokinetic Endpoints7

    Terminal half-life (t1/2), and accumulation index (AI)

    Time frame: Day1-Day11

Secondary outcomes

  1. Safety Endpoints1

    Number and proportion of subjects with treatment-emergent adverse events

    Time frame: Day1-Day11

  2. Safety Endpoints2

    Number and proportion of subjects with treatment-emergent serious adverse events

    Time frame: Day1-Day11

  3. Safety Endpoints3

    Clinically significant vital sign abnormalities after the first dose of study drug up to 30 days after the last dose

    Time frame: Day1-Day38

  4. Safety Endpoints4

    Clinically significant physical examination abnormalities after the first dose of study drug up to 30 days after the last dose

    Time frame: Day1-Day38

  5. Safety Endpoints5

    Clinically significant blood routine test abnormalities after the first dose of study drug up to 30 days after the last dose

    Time frame: Day1-Day38

  6. Safety Endpoints6

    Clinically significant urinalysis abnormalities after the first dose of study drug up to 30 days after the last dose

    Time frame: Day1-Day38

  7. Safety Endpoints7

    Clinically significant abnormal blood biochemistry from the first dose of the study drug to 30 days after the last dose

    Time frame: Day1-Day38

  8. Safety Endpoints8

    Clinically significant ECG changes after the first dose of study drug up to 30 days after the last dose

    Time frame: Day1-Day38

07

Study locations

1 site
  • Nanjing Drum Tower hospital
    Nanjing, Jiangsu 210000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Dec 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2024
First posted
Mar 22, 2024
StartActual
Sep 4, 2023
Primary completionActual
Dec 24, 2023
CompletionActual
Feb 5, 2024
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326723
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Sep 4, 2023
Primary completion
Dec 24, 2023
Completion
Feb 5, 2024
Last update
Mar 22, 2024

Study contacts

Juan Li
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion